U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07782333) titled 'A Study Evaluating TRIV-573 in Atopic Dermatitis' on Aug. 18.
Brief Summary: The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).
The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: TRIV-573
TRIV-573 (Subcutaneous injection)
DRUG: Plac...